• Active, not recruiting

NCT02538198: Phase 2 - Lenalidomide Maintenance in Plasma Cell Myeloma

Updated: Apr 25

NCT02538198: Phase 2 - Lenalidomide Maintenance in Plasma Cell Myeloma


NCT02538198: Phase 2 - Lenalidomide Maintenance in Plasma Cell Myeloma

This is a Phase 2 study to assess the good and bad effects of maintenance therapy on patients who have been treated for myeloma and no longer show signs of this type of cancer.



Sponsor:

Memorial Sloan Kettering Cancer Center


Official Title: Lenalidomide Maintenance in Plasma Cell Myeloma


ClinicalTrials.gov Identifier: NCT02538198


Official Title: Lenalidomide Maintenance in Plasma Cell Myeloma


Click here to see details on ClinicalTrials.gov

 

Lenalidomide: National Cancer Institute

Lenalidomide: MedlinePlus Drug Information

 

Dynamics of minimal residual disease in patients with multiple myeloma on continuous lenalidomide maintenance: a single-arm, single-centre, phase 2 trial

Interpretation: Serial measurements of MRD allow for dynamic assessment of risk for disease progression. Early intervention should be investigated for patients with loss of MRD negativity. Sustained MRD positivity is not categorically an unfavourable outcome and might portend prolonged stability of low-level disease.

Lancet Haematol; 2021

https://pubmed.ncbi.nlm.nih.gov/34048681/


Posts Archive